5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE). 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.
5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of the infiltrated mononuclear cell in the CNS, and significantly decreased the population of infiltrated CD4+ population. 5J-4 reduced the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in the mouse model of inflammation.